BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/27/2014 5:15:00 PM | Browse: 840 | Download: 672
Publication Name World Journal of Gastroenterology
Manuscript ID 7044
Country/Territory United States
Received
2013-11-02 14:21
Peer-Review Started
2013-11-02 20:14
To Make the First Decision
2013-11-13 14:18
Return for Revision
2013-11-14 13:25
Revised
2013-12-02 01:12
Second Decision
2014-01-05 15:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-05 15:09
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-04-24 15:47
Publish the Manuscript Online
2014-05-18 12:31
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Case Report
Article Title TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review
Manuscript Source Invited Manuscript
All Author List Ruwaida Ben Musa, Lydia Usha, John Hibbeln and Ece A Mutlu
Funding Agency and Grant Number
Corresponding Author Ece A Mutlu, MD, MS, MBA, Associate Professor of Medicine, IBD Program Director, Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Rush University, Rush Medical College, 1725 W, Harrison, Suite 206, Chicago, IL 60612, United States. ece_mutlu@rush.edu
Key Words Tumor necrosis factor inhibitor; Ulcerative colitis; Breast Cancer; Inflammatory Bowel Disease; Adalimumab
Core Tip Tumor necrosis factor (TNF)-α inhibitors are widely-used and effective treatments for many autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. However, it is believed that TNF-α inhibitors may also place patients at increased risk of cancer occurrence or recurrence. Many studies report increased risk of cancer following exposure to TNF-α inhibitors, but little has been reported for patients with cancer, receiving anti-TNF-α treatment. This is the first case of metastatic breast cancer in long term remission for 3 years in a patient treated with TNF-α inhibitors for ulcerative colitis, suggesting that patients with metastatic cancer could be treated with this class of medications without worsening.
Publish Date 2014-05-18 12:31
Citation Ben Musa R, Usha L, Hibbeln J, Mutlu EA. TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: A case report and literature review. World J Gastroenterol 2014; 20(19): 5912-5917
URL http://www.wjgnet.com/1007-9327/full/v20/i19/5912.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i19.5912
Full Article (PDF) WJG-20-5912.pdf
Full Article (Word) WJG-20-5912.doc
Manuscript File 7044-Review.docx
Answering Reviewers 7044-Answering reviewers.pdf
Copyright License Agreement 7044-Copyright assignment.pdf
Peer-review Report 7044-Peer review(s).pdf
Scientific Editor Work List 7044-Scientific editor work list.doc